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Summary
Clinical trials guidelines should offer evidence-based recommendations, and, where evidence is lacking or absent, should reflect the
considered opinion of experts in the field. Recent OsteoArthritis Research Society International (OARSI) guidelines encompass these
principles and are the result of a Task Force Workshop involving representatives from academia, regulatory authorities and industry. Areas
for continued development for trials of Structure Modifying Osteoarthritis Drugs (STMOAD) include patient selection, study duration, sample
size estimation, outcome assessment, imaging, response definition and pharmoeconomics. As developments occur in these and related
areas, guideline documents will require revision to reflect this evolution. Notwithstanding these issues, there is opportunity to identify
STMOAD class agents using current methodologies.
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Over the last 10 years, several guidance documents,
referable to osteoarthritis (OA) clinical trials, have been
published. These include recommendations from Food and
Drug Administration (FDA),1 European League against
Rheumatism (EULAR),2 International League of Associ-
ations for Rheumatology (ILAR),3 Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT),4 Osteo-
Arthritis Research Society International (OARSI),5 and
Group for the Respect of Ethics and Excellence in Science
(GR-EES).6
One of the most recent and most comprehensive docu-
ments is that published by a task force of the OARSI.5 It
deals with various aspects of clinical trial design and
provides some direction in the trialing of purported Struc-
ture Modifying Osteoarthritis Drugs (STMOAD). Current
OARSI guidelines anticipate that the metrology and meth-
odology of clinical trials will change with time. The recom-
mendations are made with the understanding that they will
require modification as new information becomes available.
Investigators, regulatory and sponsoring agencies should
be aware of the likelihood of such change and be flexible
in adapting to that change. As part of the advancement,
the incorporation of both validated and investigational
measures should be expected. Many of the recommen-
dations made in the Task Force document are supported by
published clinical research. However, some are based on
the best judgment of the Task Force and Workshop partici-
pants.5 The document provides recommendations or
guidelines, not rigid rules, for the conduct of clinical trials in
OA. The OARS Workshop5 and the OMERACT III Confer-
ence,4 that preceded it by a few weeks, were attended by
representatives from academia, industry and regulatory
agencies, and, as such, had major input from many
interested parties.
It is generally recognized that three classes of agents
may exist: (1) those that are purely symptom modifying424(Symptom Modifying Osteoarthritis Drugs—SYMOAD), (2)
those that only modify structure (STMOAD), and (3) those
that have both SYMOAD and STMOAD properties.
Structural pathology in OA occurs in various anatomical
structures and is not confined to hyaline cartilage. As a
consequence, the current capacity to measure pathological
processes and their structural sequelae is relevant to
SYMOAD drug trialing since such drugs might potentially
have positive, negative or neutral effects on various com-
ponents of joint structure. In contrast, STMOAD drugs
might theoretically prevent, retard, arrest, or reverse struc-
tural changes, and either have direct or indirect effects on
the patient’s symptomatology. Several areas, relevant to
the trialing of STMOAD, deserve further consideration.Selecting the correct ‘patients for study’
To date there are no agents which have irrefutably
demonstrated their capacity to act as STMOAD. As a
consequence, there is a relative paucity of knowledge
relating to patient selection. in longitudinal studies, joint
structure in some patients has not appreciably changed
over a 2–3 year period. This suggests that not all patients
with OA progress, or, if they do, then change is slow and
occurs over a greater number of years. Obese middle aged
women with OA, and, to a lesser extent, men, may show
more rapid progression. However, it is not known how
representative of the disease population as a whole these
subgroups are. Indeed, those with the fastest disease
progression may be the hardest in whom to stop or slow
down structural deterioration. Further research is needed to
more fully comprehend the nature of structural deterior-
ation, such that patients with early but progressive disease
might be evaluated rather than patients with relatively inert
late stage disease. The challenge of identifying at-risk
patients for the purpose of primary prevention studies
represents an even greater challenge, since not all at-risk
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frame of an interventional study. Implicit in patient selection
are ‘trade offs’ between the homogeneity of the study
population, accrual rate and generalizability of study
results.Sufficient study duration
Current guidelines suggest that study duration should be
predetermined, be at least one year, and depends on the
mode of action of the drug, the anticipated response rate,
the primary outcome variable and the length of time needed
to show a difference in comparison with a control (i.e.,
placebo group). It has been recognized that the rate and
profile of change in joint space narrowing is variable and
may be non-linear. Furthermore, the percent of OA subjects
who have been followed over 2–5 years with more modern
imaging techniques is not that large. It is likely, therefore,
that studies of several years’ duration will be required until
patient selection and imaging issues have been more fully
addressed.Adequate sample size
Sample size estimation is based either on the mean and
the standard deviation of the primary outcome measure or
on a reduction in the prevalence of an outcome event. In
STMOAD studies, the variable will be some component of
the structural image or a reduction in the percentage of
patients showing progression in the defined feature (e.g.,
joint space narrowing). The estimated number is usually
corrected for dropouts. In order for sample size estimation
to be a close approximation of the true number required for
study, (a) the mean and SD or event rate need to be closely
predictable, based on prior studies, and (b) there requires
to be an acceptable definition of the minimum clinically
important difference (MCID) for the primary outcome
variable. At the present time, the estimates of these par-
ameters has not been definitively established. For
example, longitudinal data on specialized plain radiography
and MRI are still relatively restricted. Furthermore, for the
change in structure to be important, it should have clinical
consequence, and, yet, the relationship between structure
and pain/function can be weak in some patients. It is
difficult, therefore, to be certain that, for example, a 20%
reduction in the annual rate of JSN will have clinical
consequence over a 1–2 year period.
There has been debate as to the value of structural
imaging in efficacy studies of one year in duration, How-
ever, it should be noted that such studies are usually
powered for the clinical variables. As a consequence, such
studies may be grossly underpowered to detect significant
change in structural variables and this raises the question
of the appropriateness of this contingency.Clinical outcome measures
Patient-relevant outcome measures are essential in
studies of STMOAD since they permit the identification of
any positive or negative clinical effects. The sample size
requirements for such measures are likely to be less than
those for comparing structural effects. As a consequence,
clinically-unimportant, but statistically significant, effects on
clinical variables might be detected. The better definition ofMCIDs for commonly used measures will facilitate the
interpretation of clinical data from STMOAD studies.
At OMERACT III, core set measures for future phase III
OA clinical trials were established by consensus (pain,
physical function, patient global assessment, and, for
studies ‡ 1 year, imaging). These decisions were ratified at
the OARS Task Force Workshop several weeks later.
Outcome measures, such as the WOMAC Index (hip,
knee),7 Indices of Clinical Severity (hip, knee),8 AUSCAN
Index (hand),9 Algofunctional Index (hand),10 HAQ (gener-
alized 6 OA)11 and AIMS12,13 (generalized OA), can be
used to evaluate alterations in health status.
Support for the use of patient global assessments has
been widespread, and yet there are many potential prob-
lems with this measure. In particular, the term global may
be used to describe a unidimensional measure of pain,
physical function, fatigue etc., or may be applied to a single
multi-dimensional measure that captures various aspects
of OA. The process by which patients mentally review their
symptomatology, select from that inventory, weight and
aggregate information into a single global score is
unknown. The validity and reliability of the measure is less
clear than that of the aforementioned health status
measures now in common usage. Currently, there is no
general agreement on standard wording, time-frame or
response scale for global measures in OA.
As noted previously, the exact definition of a MCID in OA
clinical trials has been elusive. Currently, the OARSI are
engaged in an evidence-based activity termed the
Response Criteria Initiative (RCI). The purpose of the RCI
is to develop a set or sets of responder criteria for future OA
hip and knee studies such that success or failure of future
treatments can be declared on an individual patient basis.
Currently, over 20 controlled clinical trials have been sub-
mitted for inclusion in the RCI, a conjoint effort attracting
the participation of academia, industry and regulatory
authorities.
The use of health-related quality of life (HRQOL) indices
in SYMOAD trials is still very limited, and, therefore, their
application in STMOAD studies remains indeterminate. It
appears that they may be less sensitive than so-called
disease-specific measures,14,15 and that comorbidities
may have a greater impact on HRQOL measures than
disease-specific measures.14 However, HRQOL measures
tap into different aspects of health, and their continued use
is to be encouraged, notwithstanding the fact that STMOAD
class drugs may have minimal or very delayed effects on
HRQOL.
There has been growing interest in attempting to
measure various aspects of non-target joint involvement in
OA. However, the instrumentation for doing this, and the
consequences for sample size, remain to be determined.
The globalization of clinical trials has necessitated the
creation of linguistically-valid alternate-language forms of
standardized health status measures. Such alternate-
language forms are available for several indices including
the WOMAC Index, Indices of Clinical Severity, AUSCAN
Index, Algofunctional Index, HAQ, AIMS and SF36. Linguis-
tic validation usually involves a complex process requiring
forward and back-translations, by fluently bilingual trans-
lators, followed by application of the alternate-language
form in a reference population in the index country.Optimum imaging
Issues relating to image acquisition, scoring and
archiving have been extensively debated and discussed.
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This issue and others, relating to the state of MRI vali-
dation, are detailed elsewhere in this journal. MRI, in
particular, potentially offers an opportunity to evaluate
multiple aspects of joint pathology in clinical trials.Response definition
The OARSI RCI will address MCID for clinical variables,
but it will not at this stage deal with setting minimum
structurally important differences (MSID) for imaging
variables.Linkage between clinical and imaging outcomes
Perhaps the most tantalizing question is that relating to
the point at which structural modification has clinical con-
sequence . The answer may be complex since relation-
ships in cross sectional observational studies have been
quite variable. While structural modification is an important
goal in itself, it is unlikely to be achieved without cost and
the occurrence of some side effects. As a result, patients,
clinicians, third-party payers and regulators will most prob-
ably require to confirm that these structural gains, do
indeed translate into desirable clinical outcomes within a
reasonable time frame.Pharmacoeconomics
Of the four basic types of health economic analyses
(cost minimization, cost benefit, cost-effectiveness, cost-
utility), most interest will likely focus on cost-effectiveness
and cost-utility analyses. For STMOAD, having clinically
apparent effects, these analyses can be approached in the
traditional fashion. However, for those STMOAD, having
only structural effects, it will be necessary to consider the
quantitation of effectiveness, and, possibly, utility in terms
of both the quantity of cartilage or other structural
features which have been conserved and also the clinical
consequence of that conservation.
In summary, clinical researchers are on the threshold of
evaluating new interventions for structure modifying effects.
There is a sense that MRI offers considerable advantage
over plain radiography, but there are reservations about
its current state of readiness. Plain radiography is more
familiar, but, as yet, confines itself largely to the measure-
ment of inter-bone distance and for quantifying radio-
graphic abnormalities against photographic standards.
Patient selection, study duration, sample size requirements
and image acquisition remain major challenges in the
evaluation of STMOAD. As developments occur in these
and related areas, guideline documents will require revision
to reflect this evolution. These issues, notwithstanding,
there is opportunity to identify active STMOAD using
current methodologies.References
1. Guidelines for the Clinical Evaluation of Anti-
inflammatory and Anti-rheumatic Drugs (Adults and
Children). US Department of Health and HumanServices. Public Health Services, Food and Drug
Administration. Rockville, MD April 1988:1215.
2. Guidelines for the Clinical Investigation of Drugs Used
in Rheumatic Diseases. European Drug Guidelines,
Series 5. World Health Organization, Regional Office
for Europe, Copenhagen, European League Against
Rheumatism March 1985:21–4.
3. Lequesne M, Brandt K, Bellamy N, Moskowitz R,
Menkes CJ, Pelletier J-P, Altman R. Guidelines for
testing slow acting drugs in osteoarthritis. J Rheuma-
tol 1994;(suppl 41):65–73.
4. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V,
Tugwell P, et al. Recommendations for a core set of
outcome measures for future phase III clinical trials in
knee, hip, and hand osteoarthritis. Consensus devel-
opment at OMERACT III. J Rheumatol 1997;24:
799–802.
5. Altman R, Brandt K, Hochberg M, Moskowitz R,
Bellamy N, Bloch DA, et al. Design and conduct of
clinical trials in patients with osteoarthritis: Recom-
mendations from a task force of the Osteoarthritis
Research Society. Osteoarthritis Cartilage 1996;4:
217–43.
6. Group for the Respect of Ethics and Excellence in
Science (GREES): Osteoarthritis Section. Recom-
mendations for the registration of drugs used in
the treatment of osteoarthritis. Ann Rheum Dis
1996;55:552–7.
7. Bellamy N. WOMAC Osteoarthritis Index-User’s Guide
111.1998.
8. Lequesne M. Indices of severity and disease activity
for osteoarthritis. Semin Arthritis Rheum 1991;20:
48–54.
9. Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hall
S, Muirden K, et al. Development of the Australian/
Canadian (AUSCAN) osteoarthritis (OA) hand index.
(Abstract). Arthritis Rheum 1997;40(Suppl):S110.
10. Dreiser RL, Maheu E, Guillou GB, Caspard J, Grouin
JM. Validation of an algofunctional index for osteo-
arthritis of the hand. Revue du rhumatisme 1995;
(English Edn)Suppl 1:43S–53S.
11. Fries JF, Spitz P, Kraines RG, Holman HR. Measure-
ment of patient outcome in arthritis. Arthritis Rheum
1980;23:137–45.
12. Meenan RF, Gurtman PM, Mason JH. Measuring
health status in arthritis: the Arthritis Impact Measure-
ment Scales. Arthritis Rheum 1980;23:146–52.
13. Meenan RF, Mason JH, Anderson JJ, Guccione AA,
Kazis LE. AIMS2. The content and properties of a
revised and expanded Arthritis Impact Measurement
Scales Health Status Questionnaire. Arthritis Rheum
1992;35:1–10.
14. Hawker G, Melfi C, Paul J, Green R, Bombardier C.
Comparison of a generic (SF-36) and a disease
specific (WOMAC) instrument in the measurement of
outcome after knee replacement surgery. J Rheuma-
tol 1995;22:1193–6.
15. March LM, Oh E-S, Cross M, Courtenay B, Schwarz J,
Coolican M, et al. A comparison of WOMAC MOS
SF-36 in OA patients undergoing joint replacement.
(Abstract) 8th APLAR Congress of Rheumatology.
April 21–26, 1996, Melbourne, Australia. Book of
Programme and Abstracts.
